FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
Research Workspace
Put TRAX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisModerate volatility — typically moves about 4% a day.
View RiskTRAX rests on advancing ANB033 trials across multiple indications, supported by positive celiac trial data. The latest Q2 FY2026 result missed, with GAAP EPS of -0.95 and a 28.4% shortfall. The desk cannot anchor a clean valuation multiple for TRAX. Its price is roughly in line with the growth forecast, though peer valuation implies about 29% upside. Management is running behind on a stated commitment, a specific weakness in the thesis. Our model puts the next-quarter miss probability near 68%. Peer multiples imply a price about 29% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-23. TRAX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering TRAX (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for TRAX in the last 4 months.
Continue this research
Compare TRAX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TRAX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put TRAX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance ANB033 clinical trials across multiple indications
Positive trial data supports clinical advancement of ANB033.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-23. EPS is implied from price ÷ P/E. Not investment advice.
Current $44.05
The last 12 months of price, then the range of analyst 12-month targets from today’s $44.05.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
